多腺苷二磷酸核糖聚合酶(PARP)抑制剂是一类利用合成致死效应来靶向DNA损伤修复缺陷肿瘤的新型靶向药物,也是第一款能够改善遗传性肿瘤患者预后的靶向治疗,彻底改变了种系BRCA1/2(gBRCA1/2)相关乳腺癌的治疗。 近日,JAMA Oncology在线发表重磅综述——“PAR...
多腺苷二磷酸核糖聚合酶(PARP)抑制剂是一类利用合成致死效应来靶向DNA损伤修复缺陷肿瘤的新型靶向药物,也是第一款能够改善遗传性肿瘤患者预后的靶向治疗,彻底改变了种系BRCA1/2(gBRCA1/2)相关乳腺癌的治疗。 近日,JAMA Oncology在线发表重磅综述——“PARP Inhibitors for Breast Cancer Treatment”,全面梳理了PARP抑制...
多腺苷二磷酸核糖聚合酶(PARP)抑制剂是一类利用合成致死效应来靶向DNA损伤修复缺陷肿瘤的新型靶向药物,也是第一款能够改善遗传性肿瘤患者预后的靶向治疗,彻底改变了种系BRCA1/2(gBRCA1/2)相关乳腺癌的治疗。 近日,JAMA Oncology在线发表重磅综述——“PARP Inhibitors for Breast Cancer Treatment”,全面梳理了PARP抑制...
Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncol. 2024 Mar 21. doi: 10.1001/...
INTRODUCTION: PARP inhibitors have shown promising results in early studies for treatment of breast cancer susceptibility gene (BRCA)-deficient breast cancers; however, resistance ultimately develops. Furthermore, the benefit of PARP inhibitors (PARPi) in triple-negative breast cancers (TNBC) remains un...
[1] Petropoulos, M., Karamichali, A., Rossetti, G.G. et al. Transcription–replication conflicts underlie sensitivity to PARP inhibitors. Nature (2024). https://doi.org/10.1038/s41586-024-07217-2 [2] Reducing the side effects of breast and ovarian cancer treatment. Retrieved Mar. 21, 20...
Wider access to testing for BRCA and other mutations, and to genetic counseling, are required to identify patients who could benefit from PARP inhibitor therapy. The advent of PARP inhibitors has potential benefits for BC treatment beyond the locally advanced/metastatic setting....
An Overview of PARP Inhibitors for the Treatment of Breast Cancer Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). This ...
PARP (poly ADP-ribose polymerase) inhibitors have recently emerged as a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) with a poor prognosis and are expected to contribute significantly to improving survival rates.Howeve
There is also a strong rationale to combine PARP inhibitors with CHEK1 inhibitors. In all these combinations, the delivery of the optimal dose of olaparib is challenging, especially if the therapeutic approach aims to move in early ovarian or breast cancer patients. Overall, Matulonis et al. ...